Long-Term Monitoring, Surveillance, and Survivorship
At a Glance
APDS1 requires individualized lifelong surveillance rather than one fixed testing schedule. Specialists may monitor lymph nodes, EBV and CMV viral loads, blood counts, lung function, and bronchiectasis while balancing imaging risks and supporting scan-related anxiety.
Because APDS1 is a lifelong condition, care involves maintaining an approach of active surveillance. While daily management focuses on preventing infections, long-term surveillance is designed to actively monitor a wide range of APDS complications, including enteropathy, autoimmunity, cytopenias, chronic viral disease, organ enlargement, growth, treatment toxicity, and the risks of lung damage (bronchiectasis) and lymphoma. Regular monitoring allows your care team to intervene quickly if changes occur [1][2].
Lymphoma Surveillance: Watching the “Overdrive”
One of the most important aspects of APDS1 care is monitoring for lymphoma. Research on large cohorts of patients with APDS1 has found that approximately 13% develop this complication at some point in their lives [3][4].
- Routine Checks: Your doctor will perform regular physical exams to feel your lymph nodes and spleen. They will also look for “B symptoms”—unexplained fevers, drenching night sweats, or unintended weight loss [5].
- The Biopsy Threshold: Because most swelling in APDS1 is benign (not cancer), your doctor will only recommend a biopsy if a node behaves suspiciously. Red flags include a node that grows rapidly, feels hard or fixed in place, or is highly symptomatic [6][7].
- Specialized Imaging: If your doctor is concerned, they may order a PET/CT scan. This scan uses a radioactive sugar to find “hot spots” of high activity. However, in APDS1, even benign immune activity can sometimes look “hot,” so a PET scan alone cannot diagnose lymphoma—it only shows the doctor where to biopsy [8][7].
Protecting Your Lungs: Bronchiectasis Monitoring
Chronic inflammation and repeated infections can cause the airways in the lungs to become permanently scarred and widened, a condition called bronchiectasis. This is very common, appearing in up to 60% of selected APDS1 patient cohorts who undergo lung imaging [9][10].
- Lung Function Tests (PFTs): You or your child may perform regular breathing tests (spirometry) to measure how much air your lungs can hold. Drops in these numbers can be an early sign of airway damage, though PFTs may not be feasible or reliable for very young children [11].
- Chest Imaging: High-resolution CT scans are useful when bronchiectasis is suspected or when symptoms/PFTs change. However, routine repeated baseline CTs for every child are not automatically appropriate because of radiation exposure. Imaging frequency is always decided by a specialist [10][12].
Monitoring Chronic Viruses: EBV and CMV
Patients with APDS1 often have trouble keeping common viruses like Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV) under control.
- EBV and Lymphoma: EBV-driven lymphoproliferation is particularly relevant because it increases the risk of lymphoma [13][6].
- CMV Reactivation: CMV is an important infection concern that requires monitoring, but it is not equivalent to an EBV lymphoma marker.
- PCR Testing: Regular blood tests (PCR) measure the “viral load.” A positive or rising PCR requires clinical context and does not by itself diagnose lymphoma or mandate an automatic treatment change [13][14].
An Illustrative Framework for Surveillance
There is no single universal APDS surveillance calendar. Testing depends heavily on age, symptoms, prior viral infection, immunosuppressive therapies, and transplant status. The following is merely an illustrative framework; you must obtain an individualized written plan from your specialist:
- Frequent Review: Physical exams (nodes/spleen), tracking a symptom log (infections, diarrhea, weight/growth), and lab tests (CBC, liver/kidney panels, EBV/CMV loads as clinically indicated) [2][13].
- Periodic Review: Pulmonary function tests and immunoglobulin (IgG) levels [11].
- As Needed: Chest CT (if respiratory status worsens) or lymph node biopsy (for concerning changes) [10][6].
Coping with “Scan Anxiety”
The frequency of testing can lead to “scan anxiety”—the stress and fear that a routine test will find a problem. This is a very real and common experience [15].
- Validate the Stress: It is normal to feel anxious before appointments.
- Focus on the Goal: Remind yourself that these tests are “early warning systems” designed for active surveillance and risk reduction.
- Support: If scan anxiety is affecting your quality of life, ask your team for a referral to a counselor or social worker who specializes in chronic illness [2].
Common questions in this guide
Is there one standard APDS1 surveillance schedule?
How is lymphoma watched for in APDS1?
How do doctors monitor bronchiectasis in APDS1?
Why are EBV and CMV viral load tests done in APDS1?
What can I do about scan anxiety during APDS1 monitoring?
Which lymph node changes should prompt a call to my APDS1 team?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Activated PI3K-delta syndrome 1.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How often should we be checking my/my child's EBV and CMV viral loads based on our specific symptoms and treatment?
- 2.Given my/my child's current lung imaging, at what point would you recommend a repeat chest CT to check for bronchiectasis progression, balancing radiation risks?
- 3.What exact changes in my/my child's 'baseline' lymph nodes should trigger an immediate call to your office?
- 4.Can we schedule a regular meeting with a specialist who can help me/my child manage the anxiety that comes with frequent medical scans?
- 5.What is your process for collaborating with a hematologist-oncologist if we notice suspicious lymph node changes?
References
References (15)
- 1
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME, Wolkewitz M, Schwab C, et al.
The Journal of allergy and clinical immunology 2023; (152(4)):984-996.e10 doi:10.1016/j.jaci.2023.06.015.
PMID: 37390899 - 2
Key outcomes in treatment of activated phosphoinositide 3-kinase delta syndrome: An e-Delphi panel study and responder threshold application.
Upton JEM, Williams KW, Cant A, et al.
PloS one 2025; (20(10)):e0333341 doi:10.1371/journal.pone.0333341.
PMID: 41091701 - 3
Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M, Moniri S, Zaki-Dizaji M, et al.
Clinical reviews in allergy & immunology 2020; (59(3)):323-333 doi:10.1007/s12016-019-08738-9.
PMID: 31111319 - 4
Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.
Barzaghi F, Moratti M, Panza G, et al.
Journal of clinical immunology 2024; (45(1)):58.
PMID: 39714594 - 5
Evaluation of Lymphoproliferative Disease and Increased Risk of Lymphoma in Activated Phosphoinositide 3 Kinase Delta Syndrome: A Case Report With Discussion.
Pham MN, Cunningham-Rundles C
Frontiers in pediatrics 2018; (6()):402 doi:10.3389/fped.2018.00402.
PMID: 30619796 - 6
Epstein-Barr Virus-Positive B-Cell Lymphoproliferative Disorder Complicated by Septic Shock in Activated PI3Kδ Syndrome: A Pediatric Case Report and Literature Review.
Zhao X, Ming X, Shang Z, et al.
Case reports in hematology 2026; (2026()):3644513 doi:10.1155/crh/3644513.
PMID: 42591980 - 7
Activated PI3K-δ syndrome presenting with cervical lymphadenopathy in a pediatric patient: a case report and review of the literature.
Huang Z, Wang Y, Wei R, et al.
Frontiers in immunology 2025; (16()):1622764 doi:10.3389/fimmu.2025.1622764.
PMID: 41019061 - 8
The Dark Side of Activated Phosphoinositide 3-Kinase-δ Syndrome 2: A Story Rewritten through FDG-PET.
Catelli A, Nanni C, Mulè R, et al.
Journal of clinical medicine 2024; (13(8)) doi:10.3390/jcm13082203.
PMID: 38673479 - 9
Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI, Chandra A, Bacon CM, et al.
The Journal of allergy and clinical immunology 2017; (139(2)):597-606.e4 doi:10.1016/j.jaci.2016.06.021.
PMID: 27555459 - 10
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME, Abolhassani H, Aghamohammadi A, et al.
Frontiers in immunology 2018; (9()):543 doi:10.3389/fimmu.2018.00543.
PMID: 29599784 - 11
How I treat: Diagnostic clues and treatment for activated phosphoinositide 3-kinase delta syndrome.
Kanegane H, Tomomasa D, Okada S
Journal of human immunity 2026; (2(5)):e20260054 doi:10.70962/jhi.20260054.
PMID: 42516311 - 12
Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM, Chandra A
Frontiers in immunology 2018; (9()):338 doi:10.3389/fimmu.2018.00338.
PMID: 29556229 - 13
Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8+ T Cell Survival, Differentiation, and Function.
Cannons JL, Preite S, Kapnick SM, et al.
Frontiers in immunology 2018; (9()):1758 doi:10.3389/fimmu.2018.01758.
PMID: 30116245 - 14
Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta.
Wentink MWJ, Mueller YM, Dalm VASH, et al.
Frontiers in immunology 2018; (9()):446 doi:10.3389/fimmu.2018.00446.
PMID: 29563914 - 15
Diagnostic odyssey of patients with the rare immunodeficiency activated PI3 kinase delta syndrome (APDS): case study from expert and patient surveys.
Wolf HM, Candotti F, Spelsberg R, et al.
Frontiers in immunology 2026; (17()):1763482 doi:10.3389/fimmu.2026.1763482.
PMID: 41859081
This APDS1 surveillance page is for informational purposes only and does not constitute medical advice. Your specialist should create and interpret an individualized monitoring plan, including decisions about imaging and biopsy.